Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 4, 2007, Pages 487-501

  Laita, Paula ^a   Cifuentes, Alicia ^a   Doll, Aurora ^a   Llorente, Cloe ^a   Cortés, Irene ^a   Parellada, Mara ^a   Moreno, Dolores ^a   Ruiz Sancho, Ana ^a   Graell, Montserrat ^b   Arango, Celso ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARM MOVEMENT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DECREASED APPETITE; DIZZINESS; DYSKINESIA; ENDOCRINE DISEASE; EYE MOVEMENT DISORDER; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PRESCRIPTION; PSYCHOSIS; RHINITIS; RIGIDITY; SALIVATION; SCHOOL CHILD; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHILD; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; HYPERPROLACTINEMIA; LONGITUDINAL STUDIES; MALE; TIME FACTORS;

EID: 34548700172     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0039     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington (DC), American Psychiatric Association, 2000.
2. Arango C, Parellada M, Moreno DM: Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 14 (Suppl 4):S471-S479, 2004.
3. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L: Drug induced weight gain, an impediment to successful pharmacotherapy: Focus on antipsychotics. Curr Drug Targets 5:279-299, 2004.
4. Campbell M, Small AM, Green WH, Jennings SJ, Perry R, Bennett WG, Anderson L: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650-656, 1984.
5. Cassady SL, Thaker GK, Summerfelt A, Tamminga CA: The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res 70:21-37, 1997.
6. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA: New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759, 2004.
7. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 161:414-425, 2004.
8. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
9. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 15:177-206, 2006.
10. Curtis LH, Masselink LE, Ostbye T, Hutchison S, Dans PE, Wright A, Krishnan RR, Schulman KA: Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 159:362-366, 2005.
11. Expert Panel on Detction Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
12. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
13. Gerlach J: Tardive Dyskinesia. Dan Med Bull 26:209-245, 1979.
14. Gerlach J. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials. Encephale. 14(Spec No):227-232, 1988.
15. Glazer WM: Review of incidence studies of tardive dyskinesia with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15-20, 2000.
16. Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A, Gutheil TG, Kaplan E: A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 47:949-956, 1990.
17. Huang TL, Chen JF: Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 80:55-59, 2005.
18. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J Clin Psychiatry 65(Suppl 9):16-20, 2004.
19. Kelly DL, Conley RR: Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 66:80-84, 2005.
20. Khot V, Wyatt RJ: Not all that moves is tardive dyskinesia. Am J Psychiatry 148:661-666, 1991.
21. Kumra S, Jacobsen LK, Lenane M, Smith A, Lee P, Malanga CJ, Karp BI, Hamburger S, Rapoport JL: Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 37:221-227, 1998.
22. Lindenmayer JP, Nathan AM, Smith RC: Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 62(Suppl 23):30-38, 2001.
23. Locascio J, Malone RP, Small AM, Kafantaris V, Ernst M, Lynch NS, Overall JE, Campbell M: Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27:119-126, 1991.
24. Magulac M, Landsverk J, Golshan S, Jeste DV: Abnormal involuntary movements in neuroleptic-naive children and adolescents. Can J Psychiatry 44:368-373, 1999.
25. Martin A, L'Ecuyer S: Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11:129-133, 2002.
26. McCreadie RG, Padmavati R, Thara R, Srinivasan TN: Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 181:135-137, 2002.
27. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L ,Vitiello B: Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142-1148, 2005.
28. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(Suppl 1):1-93, 2005.
29. Owens DGC: Drug-related movement disorders. In Movement and Allied Disorders in Childhood. Edited by Robertson MM, Eapen V. Chichester, John Wiley & Sons, pp 199-236, 1995.
30. Pappagallo M, Silva R: The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 14:359-371, 2004.
31. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML : Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12:221-229, 2002.
32. Richardson MA, Haugland G, Craig TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 148:1322-1328, 1991.
33. Sachdev P: The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull 21:451-461, 1995.
34. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
35. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487, 1984.
36. Shireman TI, Reichard A, Rigler SK: Psychotropic medication use among Kansas Medicaid youths with disabilities. J Child Adolesc Psychopharmacol 15:107-115, 2005.
37. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
38. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927-942, 2001.
39. Stigler KA, Potenza MN, Posey DJ, McDougle, CJ: Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 6:33-44, 2004.
40. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
41. Vieweg WV, Sood AB, Pandurangi A, Silverman JJ: Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 111:177-184, 2005.
42. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH: Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 337:869-873, 1997.
43. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.